JPRN-UMIN000008983已完成1 期
Assessment of safety on trastuzumab with varied dilution solution volume in HER2 positive breast cancer - Assessment of safety on trastuzumab with varied dilution solution volume in HER2 positive breast cancer(KBCSG03)
Kitasato University School of Medicine0 个研究点目标入组 18 人开始时间: 2012年9月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) with severe allergy to trastuzumab 2) Judjed ineligible based on physicians' decision
研究者
相似试验
已完成
1 期
Assessment of safety on trastuzumab with varied dilution solution volume in HER2 positive breast cancerBreast cancerJPRN-UMIN000034475Kitasato University School of Medicine9
进行中（未招募）
不适用
Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III multicenter study. - Dose optimization of TrastuzumabEUCTR2007-006060-29-ITIST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
已完成
2 期
The effect of anti-HER2 therapy in metastatic breast cancer wih HER2-negative primary tumor but HER2-positive circulating tumor cells<p>Breast cancer, borstkanker, HER2, ER, PIK3CA, CTC, circulating tumor cell, circulerende tumorcellen, metastasen, metastasis, trastuzumab, herceptin, docetaxel</p>10006232NL-OMON20549Erasmus MC Cancer Institute, department of Medical Oncology18
已完成
不适用
ong-term safety of trastuzumab in patients with HER2-positive breast cancerdecrease of left ventricular ejection fraction1001928010027656NL-OMON33506Antoni van Leeuwenhoek Ziekenhuis100
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28